BioCentury | Apr 15, 2013
Clinical News

Oral vaccine and adjuvant data

...progress. A Phase I trial of the adjuvant with a Helicobacter vaccine is also underway. Antex Biologics Inc....
BioCentury | Jul 11, 2005
Strategy

Immunizing against risk

...biodefense programs. Emergent itself is based on the assets of BioPort Corp. (Lansing, Mich.) and Antex Biologics Inc....
BioCentury | Jun 9, 2003
Company News

Antex, BioPort deal

...the acquisition was called off and BioPort instead purchased the assets (see BioCentury, March 31). Antex Biologics Inc....
BioCentury | Mar 31, 2003
Company News

Antex, BioPort deal

...As a result, ANX filed for reorganization under Chapter 11 of the U.S. Bankruptcy Code. Antex Biologics Inc....
BioCentury | Mar 24, 2003
Company News

Antex, BioPort deal

...30, 2002 was $6.8 million. ANX's cash was $1.2 million as of Sept. 30, 2002. Antex Biologics Inc....
BioCentury | Mar 17, 2003
Company News

BioPort acquiring Antex

Anthrax vaccine manufacturer BioPort (Lansing, Mich.) will acquire ANX for $3 million in cash or $3.6 million in cash and notes. ANX develops products to prevent and treat infections and related diseases. Additionally, BioPort will...
BioCentury | Mar 3, 2003
Finance

Ebb & Flow

...competition against IGEN. IGEN said it expects the appeals ruling around mid-year. Infectious disease company Antex...
BioCentury | Feb 27, 2003
Financial News

Antex withdraws offering, may sell assets

ANX withdrew its follow-on offering, and said it may be forced to merge or sell the company if it cannot raise additional capital. ANX, which is developing vaccines and immunotherapeutics for bacterial infections, posted an...
BioCentury | Feb 10, 2003
Clinical News

Tracvax: Phase I

...submitted an IND to the FDA to begin an open-label Phase I trial of Tracvax. Antex Biologics Inc....
BioCentury | Feb 3, 2003
Finance

Bio-warfare plays

...chg ($M) 1/31 mkt cap ($M) Int'l BioChemical (IBCL) Antimicrobial $0.15 $0.13 625% $10.0 $11.6 Antex...
Items per page:
1 - 10 of 86
BioCentury | Apr 15, 2013
Clinical News

Oral vaccine and adjuvant data

...progress. A Phase I trial of the adjuvant with a Helicobacter vaccine is also underway. Antex Biologics Inc....
BioCentury | Jul 11, 2005
Strategy

Immunizing against risk

...biodefense programs. Emergent itself is based on the assets of BioPort Corp. (Lansing, Mich.) and Antex Biologics Inc....
BioCentury | Jun 9, 2003
Company News

Antex, BioPort deal

...the acquisition was called off and BioPort instead purchased the assets (see BioCentury, March 31). Antex Biologics Inc....
BioCentury | Mar 31, 2003
Company News

Antex, BioPort deal

...As a result, ANX filed for reorganization under Chapter 11 of the U.S. Bankruptcy Code. Antex Biologics Inc....
BioCentury | Mar 24, 2003
Company News

Antex, BioPort deal

...30, 2002 was $6.8 million. ANX's cash was $1.2 million as of Sept. 30, 2002. Antex Biologics Inc....
BioCentury | Mar 17, 2003
Company News

BioPort acquiring Antex

Anthrax vaccine manufacturer BioPort (Lansing, Mich.) will acquire ANX for $3 million in cash or $3.6 million in cash and notes. ANX develops products to prevent and treat infections and related diseases. Additionally, BioPort will...
BioCentury | Mar 3, 2003
Finance

Ebb & Flow

...competition against IGEN. IGEN said it expects the appeals ruling around mid-year. Infectious disease company Antex...
BioCentury | Feb 27, 2003
Financial News

Antex withdraws offering, may sell assets

ANX withdrew its follow-on offering, and said it may be forced to merge or sell the company if it cannot raise additional capital. ANX, which is developing vaccines and immunotherapeutics for bacterial infections, posted an...
BioCentury | Feb 10, 2003
Clinical News

Tracvax: Phase I

...submitted an IND to the FDA to begin an open-label Phase I trial of Tracvax. Antex Biologics Inc....
BioCentury | Feb 3, 2003
Finance

Bio-warfare plays

...chg ($M) 1/31 mkt cap ($M) Int'l BioChemical (IBCL) Antimicrobial $0.15 $0.13 625% $10.0 $11.6 Antex...
Items per page:
1 - 10 of 86